1Jing You Lin Zhuang Bao Zhang Tang Wei Bo Yang Su Ying Ding Wu Li Rong Xue Wu Hong Li Zhang Yan Mei Zhang Shao Ming Yan Lu Zhang ~1Department of Infectious Diseases,The First Affiliated Hospital of Kunming Medical College,Kunming 650032,Yunnan Province,China ~2Departrnent of Hepatology,Kunming Third Municipal People’s Hospital,Kunming 650041,Yunnan Province,China.A randomized controlled clinical trial on the treatment of Thymosin-a1 versus interferon-α in patients with hepatitis B[J].World Journal of Gastroenterology,2001,7(3):411-414. 被引量：48
1Akahoshi M, Amasaki Y, Soda M, Tominaga T, Ichimaru S, Nakashima E, Seto S, Yano K. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001;24:337-343.
2Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver syndrome:a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18:588-594.
3Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D,Sokolovskaya N, Lurie Y, Bass DD. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92:73-79.
4Chilton RJ. Recent discoveries in assessment of coronary heart disease: impact of vascular mechanisms on development of atherosclerosis. J Am Osteopath Assoc 2001; 101:S1-5.
5Ganz P, Creager MA, Fang JC, McConnell MV, Lee RT, Libby P, Selwyn AP. Pathogenic mechanisms of atherosclerosis- effect of lipid lowering on the biology of atherosclerosis. Am J Med 1996; 101(4A): 10S-16S.
6Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G,Bonadonna RC, Muggeo M. Bruneck study. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome:prospective data from the Bruneck study. Diabetes Care 2003;26:1251-1257.
7Indulski JA, Lutz W. Ischaemic heart disease as an effect of obesity-related metabolic disturbances. Cent Eur J Public Health 1999; 7:122-129.
8Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease.Am Heart J 2003; 145:103-108.
9Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR,Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec cardiovascular study. Atherosclerosis 1996; 119:235-245.
10Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obesity 2004; 28:167-172.
1MINAKARI M, MOLAEI M, SHALMANI HM, et al. Liver steatosis in patients with chronic hepatitis B infection., host and viral risk factors[J]. Eur J Gastroenterol Hepatol, 2008, 21 (5} 512 -516.
2PATEL A, HARRISON SA. Hepatitis C virus infection and nonal- coholic steatohepatitisEJ]. Gastroenterol Hepatol( N Y), 2012, 8(5) : 305 -312.
3JIN X, CHEN YP, YANG YD, et al. Association between He- patic steatosis and entecavir treatment failure in Chinese pa- tients with chronic hepatitis B[J]. PLoS One, 2012, 7(3): e34198.
4FAN JG, FARRELL GC. Epidemiology of non -alcoholic fatty liv- er disease in China[J]. J Hepatol, 2009, 50(1 ): 204 -210.
5VUPPALANCHI R, CHALASANI N. Nonalcoholic fatty liver dis- ease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management [ J]. Hepatology, 2009, 49 ( 1 ) : 306 -317.
6DEMIR K, AKYUZ F, OZDIL S, et al. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? [ J]. Ann Hepatol, 2007, 6(2) : 92 -96.
